Drillon A, et al. Registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancer. Abstract PL02.08. WCLC 2019, 7-10 september, Barcelona, Spanje.
Neoadjuvant atezolizumab bij vroeg stadium tripelnegatief mammacarcinoom
dec 2020 | Borstkanker, Immuuntherapie